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Objective: Obesity is the result of positive energy balance. It can be caused by excessive energy consumption but also by decreased energy
dissipation, which occurs under several conditions including when the development or activation of brown adipose tissue (BAT) is impaired. Here
we evaluated whether iRhom2, the essential cofactor for the Tumour Necrosis Factor (TNF) sheddase ADAM17/TACE, plays a role in the
pathophysiology of metabolic syndrome.
Methods: We challenged WT versus iRhom2 KO mice to positive energy balance by chronic exposure to a high fat diet and then compared their
metabolic phenotypes. We also carried out ex vivo assays with primary and immortalized mouse brown adipocytes to establish the autonomy of
the effect of loss of iRhom2 on thermogenesis and respiration.
Results: Deletion of iRhom2 protected mice from weight gain, dyslipidemia, adipose tissue inﬂammation, and hepatic steatosis and improved
insulin sensitivity when challenged by a high fat diet. Crucially, the loss of iRhom2 promotes thermogenesis via BAT activation and beige
adipocyte recruitment, enabling iRhom2 KO mice to dissipate excess energy more efﬁciently than WT animals. This effect on enhanced ther-
mogenesis is cell-autonomous in brown adipocytes as iRhom2 KOs exhibit elevated UCP1 levels and increased mitochondrial proton leak.
Conclusion: Our data suggest that iRhom2 is a negative regulator of thermogenesis and plays a role in the control of adipose tissue homeostasis
during metabolic disease.
 2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Mammals, including humans, have a homeostatic circuitry that bal-
ances food intake with energy expenditure. However, positive energy
balance, caused by the availability of energy-rich food, combined with
sedentary lifestyles, blunts this mechanism, resulting in obesity [1]. A
variety of other factors can promote obesity, or exacerbate the effects
of positive energy balance, including genetic susceptibility, endocrine
disorders, and the microbiota [2]. Obesity drives important chronic
metabolic diseases, collectively termed metabolic syndrome,
comprising dyslipidemia, insulin resistance/type 2 diabetes, cardio-
vascular disease, and non-alcoholic fatty liver disease (NAFLD) [3].
These complications are a consequence of dealing with surplus en-
ergy, resulting in fat accumulation in non-adipose tissues, including
muscle and liver, leading to lipotoxicity-induced insulin resistance in a
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www.molecularmetabolism.comAdipose tissues play a central role in metabolic homeostasis and
metabolic disease [6] and are classiﬁed into two major types: white
adipose tissue (WAT) and brown adipose tissue (BAT). WAT stores
energy within lipid droplets (LD) [7] and, upon metabolic demand,
hydrolyzes triglycerides into glycerol and free fatty acids (FFA), to fuel
the functions of peripheral organs. WAT also plays an important
endocrine role during health and disease by secreting a range of
signaling proteins collectively called adipokines [6,8,9].
In rodents, BAT serves a fundamentally different purpose: non-
shivering thermogenesis. FFA activate uncoupling protein 1 (UCP1),
a channel that diverts protons produced by oxidative phosphorylation;
the resultant proton leakage into the mitochondrial matrix drives heat
production [10]. Substantial evidence from mouse models indicates
that BAT can counteract adiposity, insulin resistance, and hyperlipid-
emia [11]. Consequently, BAT biology and strategies to encourage
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Original Article[12,13]. An additional category of thermogenic adipocytes called
“Beige” (or “brite”) adipocytes express UCP1, but develop within the
WAT [14]. These cells are recruited during prolonged cold exposure,
exercise, or adrenergic activation, as well as by a range of other
stimulida process termed “browning” or “beiging” [15e18].
Lipid overloading within adipocytes has profound pathological conse-
quences, such as triggering the stress-induced secretion of pro-
inﬂammatory adipokines and cytokines including tumor necrosis fac-
tor (TNF), the ﬁrst cytokine implicated as a link between inﬂammation
and obesity [19]. Soluble TNF, generated by cleavage of its trans-
membrane form by the cell surface protease ADAM17 (a disintegrin
and metalloprotease-17), also called TACE (TNF-a converting enzyme
[20] plays an important role in the pathophysiology of metabolic dis-
ease. Crucially, the trafﬁcking of ADAM17 within the secretory
pathway, maturation from its pro-enzyme form [21e23], stimulation of
its proteolytic activity on the cell surface [24,25], and control of its
substrate speciﬁcity [26], all require a cofactor called iRhom2. iRhom2
is a polytopic membrane protein that is highly expressed in immune
cells, particularly macrophages, where it plays an essential role in
ADAM17 regulation [21,22]. Hence, the release of TNF from myeloid
cells requires iRhom2 [21,22].
TNF regulates the pathobiology of metabolic syndrome in several
important ways [27]. It is responsible for macrophage recruitment to
adipose tissue and the establishment of metainﬂammationdthe
chronic low grade inﬂammatory state that is established in adipose
tissue and other metabolic organs during obesity [28,29]. Metain-
ﬂammation has important pleiotropic effects on metabolic disease,
both within adipose tissue and systemically [19]. One of TNF’s major
pathological impacts is triggering insulin resistance in skeletal muscle
and adipose tissue by promoting serine phosphorylation of insulin
receptor substrate 1 (IRS-1) [30], which impairs the capacity of this
adaptor protein to mediate insulin receptor signaling. TNF also en-
hances lipolysis in adipocytes, increases circulating FFA, and promotes
leptin release from adipocytes, both of which can contribute to insulin
resistance [31]. The role of TNF in the regulation of the BAT thermo-
genic capacity remains debated [27].
Mice null for TNF or its receptors are protected from obesity-associated
insulin resistance but not from an increase in fat mass [32]. By
contrast, ADAM17 null mice, also protected from insulin resistance,
exhibit a hypermetabolic phenotype and resist weight gain in models of
obesity [33,34]. These differences in the metabolic phenotype of TNF
and ADAM17 null mice are likely associated with the fact that ADAM17
cleaves multiple cellular substrates in addition to TNF [35].
iRhom2 shares redundant functions in ADAM17 regulation with its
paralog iRhom1. Consequently, the phenotype of iRhom2 KO mice is
much milder than ADAM17 KO mice, which die perinatally with severe
abnormalities in the eyes, skin, hair, and lung [36]. By contrast,
iRhom2 KO mice appear normal but are protected from a range of
conditions, most of which involve inﬂammation, including sepsis
[21,22], arthritis [37], and lung injury [38]. However, whether global
deletion of iRhom2 impacts energy balance and/or adipose tissue
function is currently unknown.
In this work, we evaluated the contribution of iRhom2 to metabolic
syndrome. Intriguingly, we ﬁnd that iRhom2 KO mice are protected
from a range of deleterious metabolic phenotypes including obesity,
adipose tissue inﬂammation, hepatic steatosis, and insulin resistance.
We also show that iRhom2 is expressed in adipocytes, and its
expression levels are increased in brown adipocytes from obese ani-
mals. Strikingly, loss of iRhom2 enhances the capacity of the animals
to dissipate excess energy via increased adaptive thermogenesis in
BAT and through increased beiging of WAT. Consistent with this,68 MOLECULAR METABOLISM 31 (2020) 67e84  2019 The Authors. Published by Elsevier GmbH. TiRhom2-null primary adipocytes exhibit elevated levels of UCP1 and
increased mitochondrial proton leak, offering a potential mechanistic
explanation for the observed phenotypes. Overall, our data reveal a
fundamental organismal role for iRhom2 as a negative regulator of
thermogenesis.
2. RESULTS
2.1. iRhom2 is expressed in adipose tissues and its expression is
elevated speciﬁcally in BAT
To examine objectively the expression pattern of iRhom2 in vivo,
we generated a mouse strain in which the endogenous iRhom2
gene was modiﬁed to incorporate an in-frame N-terminal FLAG tag.
Strikingly, western blots on lysates from tissues isolated from
iRhom2-FLAG mice revealed that iRhom2 was signiﬁcantly
expressed in a range of metabolic organs including adipose tis-
sues, pancreas, liver, and muscle (Fig. S1A). As iRhom2 is
expressed in several major adipose depots, we focused in more
detail on these organs. Notably, iRhom2 was expressed in primary
adipocytes differentiated from progenitors from the stromal
vascular fraction (SVF) from subcutaneous WAT (sWAT) or BAT
(Figure 1A). Intriguingly, iRhom2 mRNA was upregulated in BAT
and brown adipocytes biochemically isolated from mice chronically
exposed to a high fat diet (HFD) for 30 weeks, a model for obesity/
metabolic syndrome (Figure 1B,C). We conﬁrmed that iRhom2 was
also upregulated at the protein level in BAT from animals on HFD
(Fig. S1B). In an in vitro inﬂammatory environment, iRhom2 mRNA
was also modestly upregulated in primary WT brown adipocytes
differentiated in vitro from SVF treated with TNF (Fig. S1C).
2.2. iRhom2 KO mice are protected from HFD-induced obesity,
dyslipidemia, and hepatosteatosis
The upregulation of iRhom2 levels in BAT during obesity and the fact
that iRhom2 plays a central role in ADAM17 regulation and TNF release
[21,22] led us to determine whether the ablation of iRhom2 had an
impact on the development of HFD-induced metabolic syndrome.
Notably, after challenging WT versus iRhom2 KO mice with HFD for
w30 weeks, we found that, in spite of food intake being equivalent
between genotypes (Figure 1D), iRhom2 KOs were protected from
HFD-induced obesity (Figure 1E,F,H, Fig. S1DeF). Therefore,
compared to WTs, HFD-fed iRhom2 KO mice had reduced body weight
(BW) (Figure 1E, Fig. S1D), adiposity (Figs. S1EeF), and absolute and
relative fat mass (Figure 1F,H). iRhom2 KOs were also protected from
the decrease in lean mass observed in the WT mice on HFD compared
to the respective SD-fed controls (Figure 1G,I). As predicted by the
decreased fat mass of iRhom2 KO mice, we observed a signiﬁcant
protection from HFD-induced dyslipidemia (Figure 2AeD). The most
pronounced reduction was observed in fasting cholesterolemia
(Figure 2A), which was associated with decreased levels of serum low
density lipoproteins (LDL) (Figure 2D).
Lipid accumulation in non-adipose organs is a common hallmark of
the pathophysiology of obesity [39]. As shown in Figure 2E, iRhom2
KO mice were protected from HFD-induced increased liver weight.
This was associated with a striking protection from NAFLD-
associated hepatic histopathological alterations and lipid accumula-
tion in iRhom2 KO mice (Figure 2FeJ). We conﬁrmed that the
reduced hepatic steatosis in iRhom2 KO mice correlated with
reduced triglyceride deposition rather than cholesterol (Figure 2K,L).
By contrast, the mild lipid accumulation observed in skeletal muscle
on animals maintained on HFD was similar between WT and iRhom2
KOs (Fig. S2A and B).his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: iRhom2 expression is increased in brown adipose tissue in HFD-induced obesity and iRhom2 KO mice are less prone to this disease. A Protein expression of
iRhom2 in subcutaneous and brown adipocytes differentiated in vitro from the stromal vascular fraction of 4e5 pooled WT and iRhom2 KO mice. As a loading control, we measured
p97 protein levels. Two independent experiments. B RT-PCR analysis of Rhbdf2 expression in brown adipose tissue (BAT), subcutaneous (sWAT), and epididymal (eWAT) white
adipose tissues, liver, and hypothalamus from WT mice fed with HFD for 30 weeks compared to WT fed with SD for the same extent. Two experiments with 3e4 mice per group. C
RT-PCR analysis of Rhbdf2 expression in mature brown adipocytes, stromal vascular fraction (SVF), and whole BAT tissue from HFD-fed WT mice compared to SD-fed ones. Two
independent experiments with 3 replicates pooled from 2 mice each. D Food intake of WT and iRhom2 KO fed with SD or HFD for 17 weeks. One experiment, with 6e8 mice per
group. E Body weight of iRhom2 KO and WT mice after 30 weeks of SD or HFD exposure. Three independent HFD-induced obesity experiments, with 12 WT and 11 KO in two, and
11 WT and 9 KO mice in the third were performed. The analysis of the SD-fed mice was performed on 3 groups of 4e7 mice per genotype. FeI Absolute values of fat (F) and lean
(G) mass, and percentage of fat (H) and lean (I) mass relative to body weight of the mice described above. One experiment, with 6 and 8 mice per genotype fed with SD and HFD for
17 weeks, respectively. The legend colour coding of panel D applies also to panels EeI. Error bars represent SEM; * represents p < 0.05, ** represents p < 0.01, *** represents
p < 0.001, **** represents p < 0.0001.
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Figure 2: iRhom2 KO mice are protected from dyslipidemia and NAFLD. A-D Colorimetric analysis of total cholesterol (A), triglycerides (B), HDL (C), LDL (D) in the serum of
iRhom2 KO and WT mice fed with SD and HFD for 22 weeks. E Liver weight of iRhom2 KO and WT mice fed with SD and HFD for 30 weeks. Three independent HFD-induced
obesity experiments, with 9e12 WT and 8e11 KO mice. The analysis of the SD-fed mice was performed on 2e3 groups of 3e7 mice per genotype. FeH Liver photographs (F),
histopathological classiﬁcation of NAFLD (scores ranging from no alterations (0) to a severe NAFLD phenotype (4) (G), and representative photographs of liver H-E staining (100x
magniﬁcation) (H) of iRhom2 KO and WT mice described above fed with HFD for 30 weeks. I-J Liver fat content histopathological classiﬁcation (scores ranging from within normal
limits (0) to severe fat accumulation (2) (I), and representative photographs of liver Oil red staining (100x magniﬁcation) (J) of the mice described above fed with HFD. K-L
Colorimetric analysis of liver triglycerides (K) and cholesterol (L) concentration in the animals described above fed with SD and HFD for 30 weeks. Two independent experiments
with n ¼ 6 or 12 HFD-fed mice and n ¼ 2 or 6 SD-fed mice per genotype. Scale bar ¼ 100 mm. Error bars represent SEM; * represents p < 0.05, ** represents p < 0.01, ***
represents p < 0.001, **** represents p < 0.0001.
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2.3. iRhom2 KO mice are protected from HFD-induced adipose
depot expansion
As expected from their overall reduced body weight on HFD (Figure 1E;
Fig. S1DeF), iRhom2 KO mice presented with a signiﬁcantly reduced
adipose tissue weight in all anatomical regions except eWAT, where
the effect was less marked (Figure 3AeE; Fig. S3A). Strikingly, on HFD
we observed a signiﬁcant reduction in adipocyte area in subcutaneous
and mesenteric adipose tissues from iRhom2 KO mice, indicating aFigure 3: iRhom2 KO mice fed with HFD have reduced adipose tissue depots and sm
photographs of H-E staining (200x magniﬁcation) (G, I, K, M, O) of subcutaneous (sWAT) (A
adipose tissues, and brown adipose tissue (BAT) (E, N, O) from iRhom2 KO and WT mice fe
independent HFD-induced obesity experiments, with 11e12 WT and 9e11 KO mice. The a
average WAT adipocyte size [average cross-sectional area per cell (mm2)] was determined
fed mice per genotype per experiment (3 experiments). The average BAT adipocyte size w
HFD-fed animals described above. Scale bar ¼ 100 mm. Error bars represent SEM; * rep
p < 0.0001.
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Nevertheless, there was no alteration of the adipocyte area in the
epididymal and retroperitoneal adipose tissues (Fig. 3J-M, Fig. S3D
and E).
Obesity-associated lipid loading causes brown adipocytes to lose their
characteristic multilocular appearance, becoming morphologically
more similar to white adipocytes [19,40,41]. Notably, in mice on HFD,
the adipocytes from WT BAT developed large unilocular lipid dropletsaller adipocytes. A-O Weight (A-E), adipocyte area (F, H, J, L, N), and representative
, F, G), mesenteric (B, H, I), epididymal (eWAT) (C, J, K), retroperitoneal (D, L, M) white
d with SD and HFD for 30 weeks (photographs only from HFD-fed mice samples). Three
nalysis of the SD-fed mice was performed on 3 groups of 4e7 mice per genotype. The
using a macro on H-E staining of adipose tissue from 3 HFD-fed animals and 1e3 SD-
as calculated as described previously [83] in adipose tissue samples from the SD and
resents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, **** represents
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adipocytes were protected from this phenomenon, remaining multi-
locular and smaller (Figure 3NeO; Fig. S3F).
2.4. HFD-fed iRhom2 KO mice have reduced systemic and adipose
tissue inﬂammation
When the limits of adipocyte plasticity are reached during obesity,
adipocyte stress triggers the secretion of adipokines, inﬂammatory cell
recruitment, and the release of inﬂammatory cytokines, such as TNF.
Consistent with the requirement for iRhom2 in TNF shedding in other
models [21,22,37,42,43], circulating levels of soluble TNF in iRhom2
KOs were undetectable, compared to WT controls, in serum from
animals subjected to the HFD protocol (Figure 4A). To determine the
impact of loss of iRhom2 on adipose tissue inﬂammation, we used
histopathology to score inﬂammatory cell inﬁltration. Overall, we
observed a mild protection from immune cell inﬁltration into adiposeFigure 4: iRhom2 KO mice fed with HFD have no circulating TNF and reduced fat stea
weeks. One experiment with 12 WT and 11 KO mice. B-E Histopathological classiﬁcation o
mesenteric (C), retroperitoneal (D), and epididymal (eWAT) (E) adipose tissues. Steatitis
inﬁltration, (2) mild multifocal macrophage inﬁltration, (3) moderate multifocal macrophage
independent HFD-induced obesity experiments with 11e12 WT and 9e11 KO mice. F Rep
in the H-E staining (100x magniﬁcation), with an ampliﬁcation of an area of steatitis. Scale
sWAT, eWAT, and spleen of IRhom2 KO and WT mice fed with HFD for 30 weeks. Three i
analysis of Tnf, Mcp1, Il1b, Il10, and Il6 expression in HFD-fed iRhom2 KO mice eWAT rela
Error bars represent SEM; * represents p < 0.05, ** represents p < 0.01, *** represent
72 MOLECULAR METABOLISM 31 (2020) 67e84  2019 The Authors. Published by Elsevier GmbH. Ttissues in iRhom2 KOs (Figure 4BeF), which was most obvious in
epididymal adipose tissue (Figure 4E,F), where, during obesity,
adipocyte death and inﬂammation are normally more pronounced
compared to subcutaneous adipose tissue [44]. We stained the
macrophages isolated from the adipose tissues, compared to the
spleen of HFD-fed iRhom2 KO and WT mice, conﬁrming that there was
a signiﬁcant reduction in the relative proportion of macrophages found
in the epididymal WAT of iRhom2 KO mice (Figure 4G; gating strategy
indicated in Fig. S4). Notably, this correlated with a decrease in in-
ﬂammatory cytokine/chemokine mRNA expression in iRhom2 KO
epididymal adipose tissue (Figure 4H). An exception was the increased
TNF mRNA levels in iRhom2 KOs, which we speculate to be an
attempted compensatory mechanism to mitigate the loss of TNF
shedding, as observed previously in ADAM17 tissue-speciﬁc KO mice
[45]. Hence, iRhom2 contributes to the development of an inﬂamed
environment within adipose tissues.titis. A TNF concentration in the serum of iRhom2 KO and WT mice fed with HFD for 30
f steatitis (scores 0e4) of iRhom2 KO and WT HFD-fed mice subcutaneous (sWAT) (B),
was scored using the following classiﬁcation: (0) no alterations, (1) rare macrophage
inﬁltration, (4) moderate multifocal macrophage inﬁltration with steatonecrosis. Three
resentative photographs of HFD-fed KO and WT eWAT steatitis (indicated by red arrows)
bar ¼ 100 mm. G FACS analysis showing the proportion of macrophages in the BAT,
ndependent experiments in pools of 5e6 mice tissues from each genotype. H RT-PCR
tively to WT samples. Two independent analysis of 2e3 samples from each genotype.
s p < 0.001, **** represents p < 0.0001.
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2.5. iRhom2 KO mice develop less obesity-related insulin
resistance
Next, we evaluated if the reduced inﬂammation caused by loss of
iRhom2 could delay the development of insulin resistance. Although
WT and iRhom2 KO mice had similarly raised fasting glycemia on
HFD (Figure 5A), the KOs exhibited signiﬁcantly reduced fasting
insulinemia when compared to WT (Figure 5B). This equated with a
reduced homeostatic model assessment of insulin resistance index
(HOMA-IR) (Figure 5C) and increased quantitative insulin sensitivity
check index (QUICKI) (Figure 5D) in HFD-fed iRhom2 KO mice. These
data imply that on HFD the onset of insulin resistance in WT mice
necessitates elevated insulin secretion to achieve equivalent glucose
uptake to that reached by iRhom2 KOs, which retain insulin sensi-
tivity. Consistent with this interpretation, although both genotypesFigure 5: iRhom2 KO mice are less prone to HFD-induced insulin resistance. A-D F
insulin resistance index (HOMA-IR), (C) and quantitative insulin sensitivity check index (QUI
analysis 3 experiments were performed in 11e12 WT versus 9e11 KO mice fed with HFD
analysis, 2 experiments were performed in 11e22 WT versus 9e20 KO mice fed with HFD
insulin concentration (G) during OGTT and blood glucose level during ITT (H) of iRhom2 WT
the OGTT (F) and ITT (I). Three or two independent experiments were performed for OGTT a
for all the analysis. Insulin concentration during OGTT was evaluated in 1e4 SD and HFD-f
Two independent experiments using 3e5 WT versus 3e7 KO mice fed with HFD and 1
represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, **** represents
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the HFD-fed WT mice that exhibited substantially raised basal insulin
levels, also elevated insulin secretion signiﬁcantly to achieve the
same kinetics of glucose clearance (Figure 5G). By contrast, iRhom2
KO mice maintained insulinemia equivalent to animals on standard
diet, conﬁrming that lack of iRhom2 protects against the develop-
ment of diabetes (Figure 5G) and predicts that iRhom2 KO mice are
more insulin sensitive than their WT counterparts, which was
conﬁrmed in insulin tolerance tests (Figure 5H,I). Importantly, the
reduced insulinemia in iRhom2 KOs was not a consequence of
impaired insulin biogenesis, since the pancreatic insulin content was
equivalent among all groups (Figure 5J). Together these data
emphasize that loss of iRhom2 protects from the onset of insulin
resistance.asting glycemia (A) serum insulin concentration (B) homeostatic model assessment of
CKI) (D) in iRhom2 KO and WT fed with SD and HFD for 20e22 weeks. For the glucose
and 6e7 WT versus 5e6 KO mice fed with SD. For the insulin, QUICKI and HOMA-IR
, and 3e4 WT versus 2e4 KO mice fed with SD. E, G, H Blood glucose (E) and serum
and KO mice fed with SD and HFD for 26e28 weeks. F, I AUC of glucose levels during
nd ITT, respectively. In each, 9e12 HFD-fed mice and 5e7 SD-fed controls were used
ed mice (total of 7 mice per group) from each experiment. J Pancreatic insulin content.
e5 WT versus 1e3 KO mice fed with SD for 30 weeks. Error bars represent SEM; *
p < 0.0001.
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To investigate the basis of the pronounced protection from metabolic
disease observed in iRhom2 KO mice, we analyzed WT versus iRhom2
KO mice fed with SD or HFD, by indirect calorimetry. As the protection
from HFD-induced obesity observed in iRhom2 KOs (Figure 1E,F,H,
Fig. S1DeF) was not caused by differences in food consumption
(Figure 1D), one alternative basis for the improved metabolic pheno-
types of iRhom2 KO mice is a reduced capacity to harvest dietary lipids
from food. However, iRhom2 KO mice were indistinguishable from WT
controls in their capacity to absorb triglycerides upon oral gavage
(Figure 6A), and neither the concentration of triglycerides (Figure 6B) or
cholesterol (Figure 6C) excreted in feces nor the overall mass of feces
excreted (data not shown) was signiﬁcantly different. Next, we
analyzed the energy consumption of iRhom2 KOs using indirect
calorimetry. Notably the respiratory quotient (RQ) (vCO2/vO2), was
unaltered in iRhom2 KOs, indicating equivalent fat versus carbohydrate
oxidation between both genotypes (Figure 6D). Hence, energy intake,
usage and disposal, was normal in iRhom2 KO mice.Figure 6: HFD-fed iRhom2 KO mice have no differences in energy intake but incre
iRhom2 WT and KO mice fed with SD and HFD for 26 weeks. BeC Triglycerides (B) and
Respiratory quotient (RQ) (vCO2/vO2) (D), locomotor activity (LA) (E), and cumulative energ
Results are representative of two independent experiments, with 7e8 mice per group in A
mice per genotype, fed on SD or HFD for 24e25 weeks respectively. Data shown in pane
respectively. Error bars represent SEM; * represents p < 0.05, ** represents p < 0.01,
74 MOLECULAR METABOLISM 31 (2020) 67e84  2019 The Authors. Published by Elsevier GmbH. TIf energy intake is unaltered, iRhom2 KOs must expend the energy
obtained from HFD more efﬁciently. A common obesity-associated
phenotype is a reduction in physical activity in the obese state.
Notably, consistent with iRhom2 KOs on HFD being leaner and
metabolically healthier than WT mice, iRhom2 KOs maintained a lo-
comotor activity (LA) on HFD that was broadly similar to that observed
with WT and iRhom2 KO animals on SD (Figure 6E). This difference
correlated with signiﬁcantly higher energy expenditure (EE) in iRhom2
KOs than WT animals on HFD (Figure 6F, Fig. S5A and C). By contrast,
there were no signiﬁcant differences in EE when both genotypes were
maintained on SD (Figure 6F, Fig. S5B and D). Taken together, our data
show that iRhom2 KO animals can better mitigate the excess energy
intake when subjected to HFD.
2.7. iRhom2 KO mice dissipate energy through increased BAT
thermogenesis and beiging of WAT
We looked for differences to explain the signiﬁcantly increased energy
expenditure of iRhom2 KOs on HFD. As BAT is the major organased energy expenditure. A Blood triglyceride content during lipid tolerance test of
cholesterol (C) content in one gram of dried feces of the mice described above. D-F
y expenditure (EE) (F) of iRhom2 KO and WT mice fed with SD and HFD for 17 weeks.
. Four experiments were performed in BeC, each with 2e6 (SD) or 8e9 (HFD) pooled
ls DeF are derived from one experiment, with a total of 8 and 6 mice for SD and HFD,
*** represents p < 0.001, **** represents p < 0.0001.
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Figure 7: HFD-fed iRhom2 KO mice have increased thermogenesis and browning of the white adipose tissue. A-C Thermal images (A), and BAT (B) or body (C) temperature
of iRhom2 KO and WT mice fed with SD and HFD for 19 weeks. One experiment with 8 mice per group. D RT-PCR analysis of UCP1, PGC1a, Cidea, PRDM16, and Cox8b expression
in SD-fed iRhom2 KO and HFD-fed WT and iRhom2 KO mice BAT samples compared to WT SD-fed control samples. Two experiments with 3e4 replicates in each. E, G
Representative photographs of eWAT (E) and sWAT (G) UCP1 immunohistochemistry derived from iRhom2 KO and WT mice fed with HFD for 20 weeks. Scale bar ¼ 100 mm. F, H
Graphics showing the UCP1 percentage of area stained in the eWAT (F) and sWAT (H) of the mice described above. One experiment with 8 mice per group (with 2 photographs
analyzed per mouse). I RT-PCR analysis of UCP1 in brown adipocytes differentiated in vitro from the stromal vascular fraction of 4e5 pooled WT or iRhom2 KO mice. Three
independent experiments. J RT-PCR analysis of UCP1 in immortalized WT brown preadipocytes transduced with empty vector or iRhom2-HA, differentiated in vitro and stimulated
with norepinephrine for 6 h. Two independent experiments. K HA expression in differentiated immortalized WT brown preadipocytes transduced with retrovirus containing iRhom2
cDNA fused to C-terminal HA tag (iR2-HA). As a negative control, we used the same cells transduced with retrovirus containing the empty vector (EV), and as a loading control we
measured p97 protein level. Two independent experiments. L Mitochondrial oxygen consumption rate (OCR) of brown adipocytes differentiated in vitro from the stromal vascular
fraction of 4e5 pooled WT and iRhom2 KO mice and stimulated or not with norepinephrine. The results were normalized to the protein content. Two experiments with one or two
independent samples per genotype, respectively. M Mitochondrial proton leak of the cells described in L normalized to the protein content. Error bars represent SEM; * represents
p < 0.05, ** represents p < 0.01, *** represents p < 0.001.
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Original Articleresponsible for energy expenditure [7,46] and iRhom2 levels are
elevated in BAT and brown adipocytes from obese mice (Figure 1B,C),
we next examined in detail whether the loss of iRhom2 had an impact on
BAT physiology. Strikingly, thermal imaging experiments revealed that
on HFD, iRhom2 KO animals exhibited a signiﬁcantly elevated temper-
ature (Figure 7A), with a pronounced temperature difference within the
BAT itself (Figure 7B). This effect was physiologically relevant since it
translated into a signiﬁcantly elevated overall body temperature in
iRhom2 KO mice on HFD (Figure 7C). Interestingly, and consistent with
these observations, the BAT of iRhom2 KOs had signiﬁcantly increased
levels of the key thermogenic genes UCP1 and PGC1a (Peroxisome
proliferator-activated receptor gamma coactivator 1-alpha) following a
chronic (Figure 7D) or 2 week exposure to HFD (Fig. S6A), providing a
molecular basis for the increased thermogenesis.
In agreement with the premise that loss of iRhom2 expression en-
hances the thermogenic capacity of BAT, we observed that iRhom2
mRNA levels were highest in mice maintained under thermoneutrality,
reduced under conditions where thermogenesis was triggered by sub-
thermoneutral temperatures, and increased upon acclimation from
sub-thermoneutral to thermoneutral conditions (Fig. S6B).
These data are consistent with the premise that endogenous iRhom2
acts as a brake on thermogenesis and predict that loss of iRhom2
should lead to the beiging of adipose tissue under sub-thermoneutral
conditions. Notably, the visceral (eWAT) and subcutaneous (sWAT)
adipose tissues from iRhom2 KO mice on HFD exhibited increased
UCP1 protein levels compared to WT mice (Figure 7EeH). Hence, loss
of iRhom2 enhances the thermogenic capacity of BAT and promotes
WAT beiging in response to positive energy intake.
2.8. Increased BAT thermogenesis is a cell-intrinsic feature of
iRhom2 KO brown adipocytes
As our experiments were based on global iRhom2 KO mice, we wanted
to address whether the increased thermogenic capacity in iRhom2 KO
BAT reﬂected a cell-autonomous phenotype (i.e., within brown adi-
pocytes themselves). Consistent with this premise, UCP1 mRNA levels
were elevated in primary brown adipocytes differentiated in vitro from
SVF from iRhom2 KO on SD compared to WT controls (Figure 7I),
whereas overexpressing iRhom2 in immortalized brown adipocytes
reduced the stimulation of UCP1 levels in response to norepinephrine
(Figure 7J,K). These observations suggest that the circuitry through
which iRhom2 controls UCP1 levels can be found within adipocytes
themselves.
To obtain additional insights, we studied the oxygen consumption
rate (OCR) of naïve WT versus iRhom2 KO brown adipocytes as a
readout for mitochondrial function (Fig. 7L). Notably, the major
phenotypic difference observed was an enhanced proton leak in
iRhom2 KO brown adipocytes (Figure 7M; Fig. S6CeH). This is
consistent with elevated UCP1 expression/function in iRhom2 KO
tissues. Taken together, our data demonstrate that loss of iRhom2
enhances thermogenesis, implying that iRhom2 acts as an endog-
enous brake on thermogenesis.
3. DISCUSSION
Our work identiﬁes that lack of iRhom2 protects against a range of
metabolic complications associated with diet-induced obesity,
including adipose tissue expansion, hepatosteatosis, and insulin
resistance. As anticipated, loss of iRhom2, probably through impaired
ADAM17-dependent TNF shedding, results in a less inﬂamed adipose
tissue environmentda feature known to drive many of the metabolic
phenotypes observed in our study [19].76 MOLECULAR METABOLISM 31 (2020) 67e84  2019 The Authors. Published by Elsevier GmbH. TWhile we do not rule out a role for iRhom2 in myeloid cells in driving
inﬂammation to contribute to the metabolic phenotypes observed, our
work reveals an unanticipated intimate connection between iRhom2
and BAT homeostasis, identifying iRhom2 as an inhibitor of thermo-
genesis. Our data suggest that iRhom2 regulates a cell-autonomous
circuitry that represses thermogenesis; isolated brown adipocytes
from iRhom2 KO mice exhibit elevated UCP1 levels and correspond-
ingly have enhanced mitochondrial proton leak. Additionally, the levels
of iRhom2 correlate with ambient temperature: iRhom2 mRNA levels
are highest in animals with the lowest requirement for thermogenesis,
and vice versa. Finally, the levels of iRhom2 are elevated in brown
adipocytes from obese animals. Together our data suggest that
modulation of iRhom2 levels acts as a rheostat for the control of
thermogenesis.
Speculatively, this suggests a potential mechanism whereby iRhom2
KOs are protected from metabolic syndrome; on HFD, the increased
thermogenic capacity of BAT allows animals to dissipate surplus en-
ergy more efﬁciently, avoiding excess weight gain. Moreover, we
observe that loss of iRhom2 triggers the beiging of WAT on HFD,
providing an additional basis for enhanced thermogenesis. Future
studies using tissue-speciﬁc ablation of iRhom2 are required to
address this hypothesis directly and to delineate the sequence of
phenotypic events that occur following the loss of iRhom2.
iRhom2 is required for the proteolytic activity of the cell surface pro-
tease ADAM17 [21,22], and our work identiﬁes metabolic phenotypes
common between iRhom2 and ADAM17 mutant mice [33,34,47]. For
instance, the inducible systemic KO of ADAM17 [34] or global inacti-
vation of a single ADAM17 allele [47] protects mice from obesity,
hepatosteatosis, and insulin resistance.
In another study, global ADAM17 KO mice that escape the lethality
associated with this strain [36] and survive to adulthood have
increased UCP1 expression and exhibit a hypermetabolic phenotype on
standard chow [33]. By contrast, iRhom2 KOs only exhibit signiﬁcantly
increased energy expenditure when challenged by HFD. Several po-
tential factors could account for these phenotypic differences, most
obviously the functional redundancy between iRhom1 and iRhom2 in
ADAM17 regulation, with iRhom2 having a more restricted expression
pattern than ADAM17 [48]. Hence, although the fur of iRhom2 KO mice
appears normal [49], ADAM17 KOs have hair follicle density defects
[33] that could potentially enhance heat loss, increasing thermogenic
demand at sub-thermoneutral temperatures. However, mechanisms
other than heat loss must contribute to the ADAM17 KO phenotype
since the mice exhibit an increased oxygen consumption rate when
maintained under conditions close to thermoneutrality [33]. The au-
thors also found decreased corticotropin-releasing hormone (Crh)
mRNA expression in the hypothalamic paraventricular nucleus of
ADAM17 KOs [33]. Future studies involving tissue-speciﬁc deletion of
iRhom2 or ADAM17 are required to delineate the precise mechanistic
role and site(s) of action of iRhom2/ADAM17 in metabolic regulation,
and to separate cause from effect.
Defective cleavage of TNF by ADAM17 is an obvious possibility to ac-
count for some of the phenotypes observed in our studies, including the
development of adipose tissue inﬂammation and systemic insulin
resistance [32]. Interestingly, blockade of TNF signaling has been re-
ported to improve the thermogenic capacity of BAT in obesity models
[50e52], suggesting a potential basis for the effect on BAT thermo-
genesis and WAT beiging observed here. However, loss of TNF appears
not to underpin the promotion of excessive weight gain [32], suggesting
the contribution of additional ADAM17 substrates. It remains challenging
to determine which additional ADAM17 targets are responsible, because
ADAM17 cleaves more than 80 cellular substrates [35].his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The impact of loss of iRhom2/ADAM17 can have potentially complex
effects even on TNF signaling itself. ADAM17 can cleave not only TNF
but also its receptors, TNFRI and TNFRII [36,53]. Therefore, deletion of
iRhom2 could abolish TNF signaling in some tissues and potentiate it in
others. Additionally, loss of iRhom2 could also alter the mode of TNF
signaling (e.g. whether signaling occurs predominantly through TNFRI
or TNFRII, which elicit distinct biological outcomes) [54,55]. Moreover,
blocking soluble TNF (sTNF) production would abolish autocrine,
paracrine, or endocrine TNF signaling, while increasing the relative
abundance of membrane TNF (mTNF), which preferentially activates
TNFRII [56,57]. In addition, loss of ADAM17 activity could increase the
overall TNFRI or TNFRII levels, rendering the target cell more sensitive
to TNF signaling [90].
Other substrates that may contribute to the ADAM17 KO metabolic
phenotype include multiple members of the EGFR ligand family that are
cleaved by ADAM17 to activate ErbB/EGFR family receptor tyrosine
kinases [58]. Although studies on the role of EGFR ligands in metabolic
regulation are sparse, the expression levels of the ErbB1 and ErbB4
ligand HB-EGF [59], which is highly expressed in human adipose tis-
sue, correlates with the degree of adiposity. Increased plasma levels of
HB-EGF in obese humans is positively associated with the incidence of
coronary heart disease [60]. Moreover, neuregulin 4 (Nrg4), which is
highly secreted from BAT, activates ErbB4 signaling in the liver, to
downregulate hepatic lipogenesis [61]. Speculatively, because ErbB4
can be cleaved by ADAM17 [62,63], increased cell surface levels of
ErbB4 may increase its signaling, potentially mediating some of the
anti-obesogenic effects observed in iRhom2 KOs.
Interestingly, many of the phenotypes observed in our iRhom2 KO
mice (e.g. increased BAT thermogenesis, improved insulin sensi-
tivity, reduced weight gain, and decreased hepatic steatosis) are
regulated by FGF21, a hormone secreted by the liver that acts on
adipocytes. Activation of the FGF receptors by FGF21 requires a
coreceptor, b-Klotho [64,65]. Several studies have reported that a-
Klotho, a molecule closely related to b-Klotho, is cleaved by ADAM17
[66]. However, the role of ADAM17 in controlling the levels of FGF21
receptors or b-Klotho is not established.
It is interesting to note that there are no apparent metabolic differences
between WT and iRhom2 KO mice when the animals are maintained on
SD, whereas exposure of animals to HFD reveals enhanced thermo-
genesis in iRhom2 KOs. This raises the issue of why loss of iRhom2
enhances thermogenesis only within the context of HFD. Speculatively,
one possibility is that conditions that license brown adipocytes to
engage in thermogenesis (e.g. positive energy balance) may upregu-
late iRhom2 levels as part of a negative feedback loop to prevent
uncontrolled thermogenesis. This may explain why the loss of iRhom2
results in elevated thermogenesis within the context of HFD.
An obvious question concerns what the implications of our work are for
human metabolic disease. To the best of our knowledge, no publication
has examined the impact of iRhom2 on obesity, diabetes, or BMI in
human subjects. Studies in humans have focused on dominant mu-
tations within the N-terminus of iRhom2 and their effect on hyper-
keratosis [67] and esophageal cancer [68]. The proposed mechanistic
basis of these disease-associated phenotypes is elevated EGFR acti-
vation [49].
Although ADAM17 null mutations in pediatric patients are associated
with severe skin and gastrointestinal manifestations [69], there is no
reported impact on metabolism. However, there is some evidence that,
in adults, the expression of ADAM17 in skeletal muscle is positively
associated with percentage body fat, type 2 diabetes, and lipid-
induced insulin resistance and in the augmented inﬂammation asso-
ciated with increased adiposity [70,71].MOLECULAR METABOLISM 31 (2020) 67e84  2019 The Authors. Published by Elsevier GmbH. This is an open ac
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improves insulin sensitivity in rodents, results in human studies have
been mixed. Single doses of anti-TNF biologics have no effect in short
term therapies, but some impact on insulin sensitivity has been
observed in patients undergoing longer-term TNF inhibitor treatment
for chronic inﬂammatory diseases [72e74] but not for metabolic
syndrome [75]. However, as iRhom2 or ADAM17 KO mice have
additional reported phenotypes (i.e., protection from obesity and
increased energy consumption) compared to the TNF KOs, inhibition of
the iRhom2/ADAM17 pathway could represent an alternative strategy
for intervening in obesity/metabolic syndrome.
However, over the past two decades, pharmaceutical ADAM17 inhib-
itor programs have been closed down because of cytotoxicity asso-
ciated with collateral targeting of other metalloproteases with similar
active site architectures [76]. Even if ADAM17 could be inhibited
speciﬁcally and chronically, there are additional concerns about un-
intended effects caused by systemic inhibition of ADAM17, particularly
because its loss in humans is associated with inﬂammatory bowel and
skin disease [69]. By contrast, iRhom2 KO mice lack most of the
defects associated with loss of ADAM17, exhibit mature (active)
ADAM17 in most somatic tissues, and do not exhibit epithelial defects.
However, these mice are signiﬁcantly protected from obesity and the
range of other phenotypes reported for mice defective in TNF signaling.
Given the relative absence of deleterious effects associated with
deletion of iRhom2 compared to ADAM17, the targeting of iRhom2
could be an appealing prospect for future studies for the treatment of
metabolic syndrome.
4. EXPERIMENTAL MODELS
4.1. Experimental animals
iRhom2 KO mice were the kind gift of Matthew Freeman, the Dunn
School, Oxford, UK, and have been previously described [21]. Mice
were maintained in a SPF facility in a 12-hour light/dark cycle, at
standard sub-thermoneutral conditions of 20e24 C and an average of
50% humidity, in ventilated cages with corn cob as bedding. Four
weeks-old iRhom2 KO or WT C57Bl/6 male mice were co-housed after
weaning and throughout the experiments to homogenize differences in
microbiota and other environmental conditions. They were given ac-
cess to water ad libitum and standard (SD) or high-fat diet (HFD) (SNIFF
diet D12492 60 kJ% fat, E15742: 60% of energy from fat). Typically,
mice were sacriﬁced following up to 30 weeks of exposure to SD or
HFD. Body weight was recorded weekly. Three independent HFD-
induced obesity experiments, with n ¼ 12 WT and 11 KO in two,
and n ¼ 11 WT and 9 KO in the third were performed. Typically, the
analysis of the SD-fed mice was performed on 2e3 groups of 4e7
mice per genotype. In all experiments, mice were monitored twice per
week to check for signs of discomfort or distress. A minimal interval of
1 week was maintained between metabolic measurements, to mini-
mize stress on the mice. For high fat diet experiments, mice were
housed in large cages [365  207  140 mm; ﬂoor area 530 cm2]
containing a grid beneath the food repository that prevents the food
from falling easily unto the ﬂoor of the cage. This avoids the stress
associated with animals’ fur becoming oily upon contact with the HFD.
Each large cage has a deﬁned capacity of 16 mice but we limited the
numbers of mice to 9e12 per cage to provide sufﬁcient space when
the animals grow larger, to minimize stress.
Calorimetric measurements were performed using 6e8 mice per
genotype and per diet and were conducted in temperature-controlled
(24 C) cages. After arrival at CiMUS, where the indirect calorimetry
and metabolic cage experiments were performed, the mice werecess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 77
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new facility. Both WT and iRhom2 KOs, fed on SD versus HFD, were
exposed to identical conditions during transportation and acclimation.
4.2. FLAG-iRhom2 mice
FLAG-iRhom2 mice were generated via CRISPR/Cas9 as previously
described [77]. In brief, one guide RNA (50- GGTGCTA-
CACTAACTGCAGA-30) was designed to introduce a 3 x FLAG tag into
Exon 19 of the mouse iRhom2 gene. An annealing oligo encoding the
guide RNA was inserted into the plasmid pgRNAbasic, which contains
a T7 promoter [77]. The linearized vector was used as a template for
the production of sgRNA, produced by in vitro transcription using the
MEGAshortscript T7 Kit (Life Technologies). RNA was cleaned using the
MEGAclear kit (AM1908, Life Technologies). Cas9 mRNA was pro-
duced by in vitro transcription using the mMESSAGE mMACHINE T7
Ultra Kit (Life Technologies) and plasmid pT7-Cas9 as a template [77].
A 200bp homology template (50-GCTTTCCCTTCACCAGCCGCTTCTGT-
GAGAAGTACGAGCTAGACCAGGTGCTACACGAGAATCTTTATTTTCAGGGC
GACTACAAAGACCATGACGGTGATTATAAAGATCATGATATCGATTACAAG
GATGACGATGACAAGTAACTGCAGAGATTGTGTGTCTGCCCTGGGCCGTGT
GTCTATGAACCGGTGGGGCCC-30) was designed to contain 50 and 30
arms surrounding a TEV site and 3 x FLAG sequence. Homology
template, Cas9 mRNA (10 ng/ml), and the sgRNA (10 ng/ml) were
injected into the pronuclei of fertilized C57Bl/6 oocytes using standard
procedures [78]. Genotyping from tail genomic DNA was performed
using primers ﬂanking the homology template listed in the Table of
reagents (Table 1). We conﬁrmed that the tagged form of iRhom2
retains its biological function, since macrophages isolated from mice
containing one null allele of iRhom2 and one ﬂag-tagged allele behave
similarly to heterozygous animals in their capacity to secrete TNF (data
not shown).
4.3. Metabolic measurements
Following exposure to SD or HFD for 20e22 weeks, serum was
collected after overnight fasting, and the levels of total cholesterol,
triglycerides, HDL, and LDL were measured using an enzymatic-
colorimetric kit (Spinreact). Insulin levels were calculated by ELISA
(ALPCO). Blood glucose was measured using a gluco-analyzer (Roche
Diagnostics). Oral glucose, insulin, and lipid tolerance tests (OGTT, ITT,
and LTT, respectively) were performed on conscious mice following
exposure to SD or HFD for 26e28 weeks. Glucose (1,5 g/Kg) (Sigma)
was administrated per os to overnight fasted mice. Human recombi-
nant insulin (0,9 U/Kg) (Lilly) was administrated intraperitoneally to 6 h-
fasted mice. Blood glucose was measured at 0, 15, 30, 60, 90, and
120 min. The area under the curve (AUC) (%) was calculated using the
trapezoid rule (the curve is divided into series of trapezoids and the
sum of their area is the AUC). For the LTT, olive oil (0,01 ml/kg) was
administrated per os to overnight fasted mice. Quantiﬁcation of tri-
glycerides in the serum was performed at 0, 1, 2, 3, and 4 h.
The quantitative insulin sensitivity check index (QUICKI) was calculated
using the formula 1/log [fasting glucose] þ log [fasting insulin]. Ho-
meostatic model assessment of insulin resistance index (HOMA-IR)
was calculated as ([fasting insulin] (mU/L) x [fasting glucose] (mmol/
L))/14,1. Following exposure to SD or HFD for 24e25 weeks, mouse
feces were collected after a 24 h period in order to analyze its fat
content. Samples were then dried for 1 h at 70 C. One gram of dried
feces was then homogenized with a tissue grinder in PBS. Chloroform:
methanol (2:1) was added to the homogenized samples and after
centrifugation (1000G, 10 min) the lower liquid phase (containing the
lipids) was collected and left to evaporate. Chloroform þ 1% Triton-X-
100 was added, and after evaporation, water was added and78 MOLECULAR METABOLISM 31 (2020) 67e84  2019 The Authors. Published by Elsevier GmbH. Ttriglycerides and cholesterol were measured using an enzymatic-
colorimetric kit (Spinreact).
After 30 weeks on HFD, total cholesterol and triglycerides in the livers
was measured using the same kit described above. The result was
normalized to the liver weight (mg/g). Brieﬂy, a piece of the liver
caudate lobe was homogenized in chloroform/methanol (2:1) using
TissueLyser II (Qiagen) (30 Hz, 5 min). After overnight incubation, this
mixture was centrifuged (800G, 15 min) and the supernatant was
mixed with 1/5th of a volume of 0,9% NaCl. The lower phase was then
dried out and butanol/(Triton X-100:methanol) (2:1) was added to
perform the colorimetric analysis. Insulin extraction from the pancreas
was performed using the method described by Rastogi et al. [79].
Pancreatic insulin content was measured using the kit described
above.
4.4. Calorimetric measurements
Animals were analyzed for energy expenditure (EE), respiratory quo-
tient (RQ), and locomotor activity (LA) using a calorimetric system
(LabMaster; TSE Systems; Bad Homburg, Germany) as previously
shown [80e82].
4.5. Macroscopic analysis
After exposure to HFD for 30 weeks, mice were sacriﬁced and blood
was collected by cardiac puncture. After perfusion with PBS, brown
adipose tissue (BAT), dorsal subcutaneous fat (sWAT), epididymal
adipose tissue (eWAT), mesenteric fat, retroperitoneal fat, spleen, liver,
pancreas, and limb muscle were collected. All the tissues were
weighed, except for the muscle.
4.6. Western blotting
SVF-derived primary adipocytes were washed in PBS and lysed for
10 min on ice in TX-100 lysis buffer (1% Triton X-100, 150 mM NaCl,
50 mM TriseHCl, pH 7.4) containing complete protease inhibitor
cocktail (Roche). Tissues from FLAG-iRhom2 and WT mice were lysed
in a modiﬁed RIPA buffer (1% Triton X-100, 150 mM NaCl, 50 mM
TriseHCl, pH 7.4, 1 mM EDTA, 1% Sodium Deoxycholate, 0,1% SDS)
containing complete protease inhibitor cocktail (Roche) in a Tissue-
Lyser II (QIAGEN). The samples were then quantiﬁed, normalized, and
denatured with LDS at 65 C for 15 min. The lysates were fractionated
by SDS-PAGE and transferred onto PVDF membranes. After blocking
with 5% milk in TBS-T for 30 min, the membranes were cut and
incubated overnight with the primary antibodies mouse anti-Flag HRP
(1:1000; A8592; Sigma) and rabbit anti-GAPDH (1:2000; 2118, Cell
Signaling Technology), rabbit anti-iRhom2 (1:500; produced in house),
mouse anti-p97 ATPase (1:1000; 65278, Progen), mouse anti-HA
(1:5000; 12013819001 Roche). The following day, the membranes
were washed and incubated with the secondary antibody anti-rabbit
HRP (1:5000; 1677074P2, Cell Signaling Technology) or anti-mouse
(1:5000; 1677076P2, Cell Signaling Technology). After washing,
protein bands were detected using ECL.
4.7. Histopathological analysis
The collected samples were processed to parafﬁn-embedded sec-
tions (3 mm sections) and stained with H-E (Sigma). Histopathological
analysis was performed by a pathologist in a blinded manner. Sec-
tions were examined under a Leica DMLB2 microscope and images
were acquired with a Leica DFC320 camera. The extent of NAFLD
was scored using the following classiﬁcation: (0) no alterations, (1)
mild hepatocyte swelling/tumefaction with even cytoplasm vacuoli-
zation, (2) moderate hepatocyte swelling/tumefaction with uneven
hepatocyte vacuolization, (3) marked hepatocyte swelling/his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tumefaction with uneven hepatocyte vacuolization and mild to few
ballooning, (4) equal to (3) plus moderate to marked hepatocyte
ballooning. Oil red staining (Sigma) was performed on 8 mm liver and
muscle cryosections, from samples ﬁxed in 10% formalin solution for
48 h, dehydrated in 30% sucrose, and snap frozen in liquid nitrogen
embedded in OCT. The liver and muscle fat content was scored using
the following classiﬁcation: (0) within normal limits, (1) mild to
moderate, and (2) severe. WAT and BAT were scanned into digital
images (NanoZoomer-SQ Digital slide scanner-Hamamatsu) and
analyzed using Fiji software. The average WAT adipocyte size
[average cross-sectional area per cell (mm2)] was determined using a
macro on H-E staining of adipose tissue from 3 HFD-fed animals and
1e3 SD-fed mice per genotype per experiment (3 experiments). The
applied macro can be provided under request. The average BAT
adipocyte size was calculated as described previously [83]. Brieﬂy,
ﬁve low-power ﬁeld images were acquired at regular spatial in-
tervals, after which the diameters of a representative number of cells
in each ﬁeld were measured by an observer blinded to the conditions.
Steatitis was scored using the following classiﬁcation: (0) no alter-
ations, (1) rare macrophage inﬁltration, (2) mild multifocal macro-
phage inﬁltration, (3) moderate multifocal macrophage inﬁltration, (4)
moderate multifocal macrophage inﬁltration with steatonecrosis.
4.8. Adipocyte culture
Interscapular BAT and sWAT from 5 to 6 iRhom2 KO and WT 4-6-
week-old mice fed with SD was combined, minced and digested in
2 ml of Hank’s balanced salt solution (Biowest) supplemented with
1 mg/ml Collagenase (Fisher Bioreagents), 2.2 mg/ml Dispase II
(Roche) and 10 mM CaCl2 at 37 C in a shaker for 30 min. DMEM-F12
(Biowest) was added to stop digestion. Solution was ﬁltered through a
100 mm strainer and the ﬁltrate centrifuged at 4 C, 500G for 10 min.
The pellet was resuspended in DMEM-F12 and ﬁltered through a
40 mm strainer and the ﬁltrate centrifuged at 4 C, 500G for 5 min. The
resultant pellet was thereafter resuspended in complete medium
(DMEM-F12 supplemented with 10% new born calf serum, 1%
Penicillin-Streptomycin solution 100X, 10 mg/ml gentamicin sulphate
(Sigma), and 2.5 mg/ml Amphotericin B (Life Tech)) and plated in
10 cm dish. The cells were incubated at 37 C and 5% CO2. For
adipocyte differentiation, plates were coated with collagen I, rat tail
(Corning). Conﬂuent cultures were exposed to induction medium
(complete medium containing 10 mM dexamethasone, 2 mM rosigli-
tazone (Cayman), 1 mgml1 insulin (Sigma), 1 mM 3-isobutyl meth-
ylxanthine (AppliChem), and 2 nM 3,30,5-Triiodo-L-thyronine (Sigma))
on day 0 and post induction day 2. From post induction day 4 until day
6 cells were exposed to maintenance medium (complete medium
supplemented with 1 mgml1 insulin and 2 nM T3). Differentiated
primary adipocytes were treated for 8 h with mouse TNF (10 ng/ml,
410-MT-010/CF, R&D) or with an anti-TNF antibody (1 mg/ml, AF-410,
R&D) and compared to nontreated cells.
4.9. Retroviral transduction
HEK293 ET packaging cells (1  106) were transfected with pCL-Eco
packaging plasmid [84] plus pM6P.BLAST empty vector (kind gift of F.
Randow, Cambridge, UK), or pM6P containing mouse iRhom2 WT
cDNA fused to a C-terminal HA tag, or SV40 Large T Ag. WT brown
preadipocytes from a WT newborn mouse was immortalized as pre-
viously described [85]. In summary, isolated cells were split in two and
seeded in a 35 mm plate at 40% conﬂuence and one well was
transduced with 2 ml of SV-40 supernatant supplemented with poly-
brene 8 mg/mL twice with a 24 h interval. The non-transduced cells
were used as control. Then, the immortalized cells were transducedMOLECULAR METABOLISM 31 (2020) 67e84  2019 The Authors. Published by Elsevier GmbH. This is an open ac
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with polybrene 8 mg/mL, and selected with blasticidin (8 mg/mL) for 2
days to generate stable cell lines. These cells were differentiated as
mentioned above and incubated for 5 h with 0.4 mM or 0.04 mM of
norepinephrine (Sigma) in DMEM F12 with 2% free fatty acid BSA
(EMD Millipore) or only in the medium.
4.10. Seahorse assay
Oxygen consumption rate (OCR) was measured using a Seahorse
XFe96 analyzer (Agilent Tech.) and the Seahorse XF Cell Mito Stress
Test Kit according to instructions from the manufacturer. Speciﬁcally,
primary brown preadipocytes pulled from 3 to 4 mice BAT were plated
on collagen-coated Seahorse XF96 plates (10.000 cells per well) and
differentiated as mentioned above. Cells were incubated for 5 h in
medium alone (DMEM F12 with 2% free fatty acid BSA; EMD Millipore)
or with medium containing 0.4 mM norepinephrine (Sigma). Then, they
were washed twice with warm Seahorse XF Assay Medium (pH 7.4,
1 mM sodium pyruvate, 2 mM L-glutamine, 10 mM glucose), and XF
Assay Medium (180 mL) was added per well. Cells were incubated in a
non-CO2 incubator (37 C; 1 h) prior to assay. The analyzer was
programmed to calibrate and equalize samples, followed by 3 baseline
measurements (3 min each) and mixing (3 min) between measure-
ments prior to inhibitor injection. The inhibitors were injected in the
following order: Oligomycin (2 mM); FCCP (1 mM); Rotenone/Antimycin
A (0.5 mM). Three measurements (3 min each) were made following
each injection with 3 min mixing between measurements. A volume of
20 ml of 10x TX-100 lysis buffer with protease inhibitor (described
above) was added and the protein content of 2 replicates per condition
was quantiﬁed for normalization.
4.11. Immunohistochemistry
Detection of UCP1 in WAT was performed using anti-UCP1 antibody
(1:500; ab10983; Abcam) as previously reported [86e88].
4.12. Flow cytometry
Adipose tissue samples were digested in 1% collagenase H solution
(Sigma) (1 h, 37 C, with shaking). Spleens were mashed through a
70 mm cell strainer. The digested cells were centrifuged (5 min, 4 C,
2000 rpm), and red blood lysis buffer was added (9 vol. NH4Cl and 1
vol. Tris-Cl). The cells were washed and ﬁltered through a 70 mm
strainer. Cells were incubated in Fc Block, clone 2.4G2 (1:100, pro-
duced in-house) and staining was then performed with anti-mouse
CD45.2-PE, CD11b-FITC (1:100; produced in-house), and F4/80-
A647 (1:100; 123122; Biolegend). After washing in PBS plus 2%
new born calf serum, DAPI (0.2 mg/mL; Invitrogen) was added and the
samples were analyzed using a Cyan ADP analyzer (Beckman Coulter)
with FlowJo software, version 10.2. The gating strategy used is shown
in Figure S4.
4.13. Quantitative transcriptional analysis
Interscapular BAT from iRhom2 KO and WT mice, and liver, hypo-
thalamus, sWAT, and eWAT from WT mice fed with SD or HFD for 30
weeks were snap frozen in liquid nitrogen until RNA extraction (NZY-
Tech). The same was applied to adipocytes differentiated in vitro.
Interscapular BAT from 2 WT mice fed with SD and HFD for 30 weeks
was combined, minced and digested as described above. The digested
samples were ﬁltered and centrifuged at 400G for 7 min at room
temperature. The supernatant was collected, ﬁltered, and after
standing for 10 min, 1 ml was collected from the top layer to obtain
mature brown adipocytes. The pellet (stromal vascular fraction or SVF)
was washed twice. RNA was extracted from mature adipocytes, SVFcess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 79
Table 1 e Key resource table.
Reagent or Resource Source Identiﬁer
Antibodies
Mouse anti-Flag HRP Sigma A8592
Mouse anti-p97 ATPase Progen 65278
Rabbit anti-GAPDH Cell Signaling Technology 2118
Mouse anti-HA-HRP Roche 12013819001
Anti-rabbit HRP Cell Signaling Technology 1677074P2
Anti-mouse HRP Cell Signaling Technology 1677076P2
Rabbit anti-iRhom2 Instituto Gulbenkian de Ciência Produced in house
Rabbit anti-UCP1 Abcam Ab10983
Anti-mouse CD45.2-PE Instituto Gulbenkian de Ciência Produced in house
Anti-mouse CD11b-FITC Instituto Gulbenkian de Ciência Produced in house
Anti-mouse F4/80-A647 Biolegend 123122
Goat anti-TNF R&D AF-410
Chemicals/Reagents
Albumin bovine serum fraction V fatty acid free EMD Millipore 126575
Amphotericin B Life Tech 04195780D
Calcium Chloride (CaCl) Sigma 21114
Collagenase Fisher Bioreagents BP2649-1
Collagenase H Solution Sigma 11074059001
Collagen I Rat Protein, Tail Corning 354249
Chloroform Acros 10122190
DAPI ThermoFisher Scientiﬁc D1306
D-(+)Glucose Sigma G8270
Dexamethasone Cayman CAYM11015-1
Dispase II Roche 4942078001
DMEM-F12 medium Biowest L0092-500
Dulbecco’s Phosphate-Buffered Saline Zen-Bio DPBS-1000
Eosin Y Sigma 230251
Ethanol absolute VWR 20821.330
Ethylenediaminetetraacetic acid (EDTA) Fisher Chemical 10080060
Fc Block, clone 2.4G2 Instituto Gulbenkian de Ciência Produced in house
Fetal Bovine Serum PAN Biotech P30-3401
Gentamicin Sulphate Sigma G1272
Hematoxylin Sigma H3136
Hanks’ Balanced Salt Solution Biowest L0611-500
High-Fat Diet SNIFF diet D12492
Hydrochloric acid 37% (HCl) VWR 20252.290
HRP Sigma A8592
Insulin Solution from Bovine Pancreas Sigma I0516
New Born Calf Serum Biowest S075H-500
()-Norepinephrine (+)-bitartrate salt Sigma A0937
NZYol NZYTech MB18501
Penicillin-Streptomycin Solution 100 x Biowest L0022-100
Protease Inhibitor Cocktail Roche 11836153001
Rosigliatozone Cayman CAYM71740-10
Sodium Chloride (NaCl) VWR 27810.295
Sodium Deoxycholate Sigma 30970
Sodium Dodecyl Sulfate (SDS) Fisher BioReagents Cas151-21-3
Sodium pyruvate Sigma P5280
TRIS Base VWR PROL33621.260
Triton X-100 Fisher Chemical T3751108
3-isobutyl-1-methylxanthine (IBMX) AppliChem A0695.0500
3,3’,5-Triiodo-L-thyronine sodium salt (T3) Sigma T6397
Critical Commercial Kit Assays
Cholesterol CHOD-POD-Enz-Color Spinreact 201001092
HDL c-D (HDL Cholesterol D) Spinreact 1001096
LDL c-D (LDL Cholesterol D) Spinreact 41023
High-Capacity cDNA reverse transcription kit ThermoFisher Scientiﬁc 4368814
MEGAshortscript T7 Transcription Kit Life Technologies Am1354
MEGAclear Kit Life Technologies AM1908
mMESSAGE mMACHINE T7 Ultra Kit Life Technologies AMB1345
Mouse Insulin ELISA ALPCO 80-INSMS-E01, E10
RNA extraction Kit NZYTech MB13402
Seahorse XF Cell Mito Stress Test Kit Agilent Technologies 103015-100
SuperScript III First-Strand Synthesis SuperMix for q-RT-PCR ThermoFisher Scientiﬁc 11752-050
Triglycerides GPO/POD-Enz-Color Spinreact 201001313
Mouse recombinant TNF R&D 410-MT-010/CF
Mouse Strains
iRhom 2 KO Matthew Freeman, Dunn School, Oxford, UK [21]
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Table 1 e (continued )
Reagent or Resource Source Identiﬁer
C57BL/6 WT Instituto Gulbenkian de Ciência Produced in house
FLAG-iRhom2 Instituto Gulbenkian de Ciência Produced in house
Oligonucleotides Sequences
Cidea forward 5’ TGCTCTTCTGTATCGCCCAGT 3’
Cidea reverse 5’ GCCGTGTTAAGGAATCTGCTG 3’
Cox8b forward 5’ GAACCATGAAGCCAACGACT 3’
Cox8b reverse 5’ GCGAAGTTCACAGTGGTTCC 3’
Gapdh forward 5’ AACTTTGGCATTGTGGAAGG 3’
Gapdh reverse 5’ ACACATTGGGGGTAGGAACA 3’
Gnb1 forward 5’ ccagttctggagacaccacat 3’
Gnb1 reverse 5’ ggagcaagagacaggctca 3’
Gnb2 forward 5’ ggcaaaaatctatgccatgc3 3’
Gnb2 reverse 5’ tgatgagctttccgtcctg 3’
Il1 forward 5’ GAAGAAGAGCCCATCCTCTG 3’
Il1 reverse 5’ TCATCTCGGAGCCTGTAGTG 3’;
Il6 forward 5’ ACGGCCTTCCCTACTTCACA 3’
Il6 reverse 5’ CATTTCCACGATTTCCCAGA 3’
Il10 forward 5’ GCTCTTACTGACTGGCATGAG 3’
Il10 reverse 5’ CGCAGCTCTAG GAGCATGTG 3’
Mcp1 forward 5’ GGAAAAATGGATCCACACCTTGC 3’
Mcp1 reverse 5’ TCTCTTCCTCCACCATGCAG-3’
Pgc1a forward 5’ CCCTGCCATTGTTAAGACC 3’
Pgc1a reverse 5’ TGCTGCTGTTCCTGTTTTC 3’
PRDM16 forward 5’ CAGCACGGTGAAGCCATT 3’
PRDM16 reverse 5’ GCGTGCATCCGCTTGTG 3’
Psmb2 forward 5’ gagggcagtggagcttctta 3’
Psmb2 reverse 5’ aggtgggcagattcaagatg 3’
Rhbdf2 forward 5’ GCTCAACCGAAGCTATCGAC 3’
Rhbdf2 reverse 5’ ACGAACGTCAGCCAGTAGGT 3’
Tbp forward 5’ CAAACCCAGAATTGTTCTCCTT 3’
Tbp reverse 5’ ATGTGGTCTTCCTGAATCCCT 3’
Tnf forward 5’ ATGAGCACAGA AAGCATGATC 3’
Tnf reverse 5’ TACAGGCTTGTCACTCGAATT 3’;
Ucp1 forward 5’ ACTGCCACACCTCCAGTCATT 3’
Ucp1 reverse 5’ CTTTGCCTCACTCAGGATTGG 3’
Ywhaz forward 5’ ttacttggccgaggttgct 3’
Ywhaz reverse 5’ tgctgtgactggtccacaat 3’
FLAG-iRhom2 forward 5’ ACATTACCTTCGGCACCAGCG 3’
FLAG-iRhom2 reverse 5’ ATCTGGAGTCAGCCTTGAGT 3’
Taqman Probes
Actb ThermoFisher Scientiﬁc-Applied Biosystems ID-Mm00607939_s1
Rhbdf2 ThermoFisher Scientiﬁc-Applied Biosystems ID-Mm00553469_m1
Plasmids
pCL-Eco Matthew Freeman, Dunn School, Oxford, UK [84]
pT7-Cas9 Instituto Gulbenkian de Ciência [77]
pM6P.BLAST empty vector F. Randow, Cambridge, UK
pM6P.BLAST iRhom2-HA Instituto Gulbenkian de Ciência
SV40 Large T Ag Matthew Freeman, Dunn School, Oxford, UKand whole tissue using NZYol (NZYTech), followed by puriﬁcation in
columns (NZYTech). In the case of BAT from mice exposed to different
temperatures, RNA was extracted from 50 mg of tissue using the Trizol
reagent. First-strand cDNA was synthesized from total RNA using the
SuperScript III First-Strand Synthesis SuperMix or the High-Capacity
cDNA Reverse Transcription Kit (ThermoFisher Scientiﬁc). Real-time
PCR analysis was performed using the comparative CT method [89].
Gene expression was normalized to Gapdh, Actin or to the geometrical
average of 5 different genes (Tbp, Ywhaz, Psmb2, Gnb2, and Gnb1).
The primers sequence and Taqman probes used are listed in the
Table of reagents (Table 1).
4.14. Statistics
To compare single measurements between control and test groups,
unpaired t test with Welch’s correction or the ManneWhitneyeMOLECULAR METABOLISM 31 (2020) 67e84  2019 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.comWilcoxon test were used. For repeated measurements, the two-way
ANOVA was used. The statistical analysis was performed using
GraphPad Prism, version 6. Results are presented as average  SEM.
P-values <0.05 were represented as (*), <0.01 as (**), <0.001 as
(***), and <0.0001 as (****).
4.15. Study approval
Animal procedures carried out at Instituto Gulbenkian de Ciência were
approved by the Portuguese national regulatory agency (DGAV e
Direção Geral de Alimentação e Veterinária) and by the ethics and
animal welfare committees of Instituto Gulbenkian de Ciência. Ex-
periments performed at the University of Santiago de Compostela,
Spain, were performed in agreement with the International Law on
Animal Experimentation and were approved by the USC Ethical Com-
mittee (Project License 15010/14/006).cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 81
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